Viral wheeze in pre-schoolers: the AU general practice approach

About one in three Australian children wheeze at least once before they start school. Pre-school wheeze is the commonest reason for unplanned paediatric emergency department presentations in autumn and winter, peaking at twelve to twenty-four months during rhinovirus and RSV season. Most episodes resolve with a salbutamol puffer and good technique. The challenge for general practice is identifying the small proportion who have multi-trigger wheeze and atopic disease heading toward true asthma — and correcting the widespread over-use of oral steroids in children for whom evidence says they provide no benefit.

This page covers children under five years only. For children six years and older, see the parent page on asthma. For bronchiolitis in infants under twelve months, see bronchiolitis and croup.

A. Core clinical — the AU general-practice framework

Two phenotypes: EVW and MTW

The Australian Asthma Handbook — Children 1–5 and the GINA 2024 under-5 guideline classify pre-school wheeze into two clinically actionable patterns:

Episodic viral wheeze (EVW, ~50%): Wheeze triggered almost exclusively by viral upper respiratory infections (rhinovirus, RSV, parainfluenza, human metapneumovirus). The child is completely well between episodes. No atopic features. Most resolve by school age with low progression to true asthma. Oral steroids do not work in this group.

Multi-trigger wheeze (MTW, ~50%): Wheeze triggered by viruses and exercise, laughter, cold air, aeroallergen exposure, or cigarette smoke. Symptoms may persist between colds as a nocturnal cough. Associated with eczema, food allergy, allergic rhinitis, or a parent with asthma. Higher rate of progression to school-age asthma — these children are likely experiencing early true asthma.

modified Asthma Predictive Index (mAPI)

The mAPI (Castro-Rodríguez, AJRCCM 2000) helps stratify risk of school-age asthma. Applies when a child has four or more wheeze episodes per year, at least one of which was physician-diagnosed.

≥1 major criterion: parental asthma · physician-diagnosed atopic dermatitis · aeroallergen sensitisation (skin-prick or specific IgE) OR ≥2 minor criteria: physician-diagnosed food allergy · peripheral eosinophils ≥4% · wheeze apart from colds

A positive mAPI gives approximately 76% positive predictive value for asthma at age six to thirteen; a negative mAPI gives approximately 95% negative predictive value. mAPI informs the decision to trial maintenance inhaled corticosteroids in MTW — it does not independently trigger treatment.

History

• Characterise the wheeze: viral-only triggers versus multiple triggers; frequency, severity, hospital admissions, prior oral steroid courses; response to salbutamol (an unequivocally positive bronchodilator response is informative)
• Atopy screen: eczema (current and past), food allergy, allergic rhinitis, anaphylaxis, family history — five mAPI inputs gathered here
• Growth and feeding: failure to thrive plus recurrent wheeze is a cystic fibrosis red flag
• Household exposures: tobacco smoke, vaping, indoor mould, pets, crowding — household smoke roughly doubles wheeze frequency
• Immunisation status: influenza, COVID-19, RSV nirsevimab if eligible
• Red-flag review: sudden choking onset (foreign body aspiration); chronic productive cough or finger clubbing (bronchiectasis or cystic fibrosis); recurrent severe infections (immunodeficiency); persistent stridor (tracheomalacia or vascular ring)

Examination

• Vital signs: respiratory rate (>40 per minute in 1–5 year-olds is elevated), heart rate, SpO₂ on room air — SpO₂ below 92% is moderate-severe
• Work of breathing: tracheal tug, subcostal or intercostal recession, accessory muscle use, head-bob in infants, nasal flaring; speech assessment (sentences vs phrases vs words)
• Auscultation: bilateral polyphonic expiratory wheeze is the asthma-spectrum pattern; unilateral wheeze suggests foreign body aspiration — a bronchoscopy decision; silent chest is pre-arrest
• Atopic stigmata: eczema, Dennie–Morgan lines under the eyes, allergic shiners, allergic salute
• Growth plot: weight and height on percentile chart; failure to thrive triggers cystic fibrosis investigation

Investigations

Diagnosis is clinical — no test confirms pre-school asthma. Spirometry is not feasible under five to six years of age and is not recommended in this age group (Australian Asthma Handbook — Children 1–5).

Investigations are used for differential diagnosis and severity assessment:

• Pulse oximetry: mandatory at every acute visit
• FBC with differential and total/specific IgE: useful when mAPI minor criteria are being evaluated
• CXR: first severe presentation, suspected foreign body, suspected pneumonia, or atypical course
• CF newborn bloodspot screen: confirm result was completed and negative
• Nasopharyngeal PCR panel: not routine; consider at hospital admission

B. Acute management — the salbutamol spacer-first approach

Severity-guided management

Per RCH Melbourne CPG — Asthma acute 2024 and eTG paediatric respiratory:

Severity	Features	Management
Mild	Talking in sentences, mild wheeze, RR <40, SpO₂ ≥94%	Salbutamol 6 puffs (≤4 yr) / 12 puffs (≥4 yr) via spacer and face-mask; every 20 min × 3 if needed; discharge with safety-netting if sustained response
Moderate	Phrases, audible wheeze, RR 40–60, SpO₂ 92–94%, mild recession	As mild; oral prednisolone 1 mg/kg/day × 3 days only if MTW phenotype or established asthma features
Severe	Words only or silent chest, RR >60, SpO₂ <92%, marked recession, distress	O₂ to SpO₂ ≥94%; salbutamol back-to-back MDI or nebulised; ipratropium 4–8 puffs every 20 min × 3; oral prednisolone 2 mg/kg; IV magnesium sulfate 40–50 mg/kg (max 2 g) over 20 min in ED; admit
Life-threatening	Silent chest, exhaustion, cyanosis, drowsiness, apnoea	Call 000; continuous high-flow O₂; continuous nebulised salbutamol; PICU transfer

The steroid evidence (read this carefully)

The MIST trial (Panickar NEJM 2009) — 700 pre-schoolers randomised to oral prednisolone versus placebo — found no reduction in admission duration, symptom scores, or salbutamol use in virus-induced wheeze without persistent asthma features. The concurrent Schuh 2009 NEJM trial of oral dexamethasone found similar negative results.

Bottom line: routine oral steroids for a first-time episode of pure viral wheeze in a previously well pre-schooler without atopic background or established asthma trajectory are not supported by evidence. The RCH CPG 2024 restricts oral prednisolone to moderate-severe wheeze in children with the multi-trigger phenotype or prior preventer use.

Maintenance preventers

Scenario	Preferred regimen	Evidence
EVW, ≤3 episodes/year, well between	Salbutamol PRN only — no preventer	PEAK NEJM 2006: ICS no disease-modifying effect in EVW
MTW, atopic, mAPI positive, ≥4 episodes/year or 1 severe	Trial ICS 4–12 weeks: fluticasone propionate 50–100 µg BD or budesonide 200 µg BD via spacer	PEAK NEJM 2006; GINA 2024; cease at 12 weeks if no clear benefit
Montelukast	Second-line or add-on; PBS Authority Streamlined ≥6 months	TGA Boxed Warning 2020: neuropsychiatric ADRs — counsel and document

C. Asthma action plan, vaccination, and the atopic march

Written action plan — every wheeze family

Every child with two or more documented wheeze episodes should leave with a written pre-school Asthma Action Plan from Asthma Australia. The plan covers:

• Home reliever dose (6 or 12 puffs) and timing
• When to repeat (every 20 min × 3)
• Emergency triggers for calling 000 (not responding, drowsy, blue lips, inability to talk)
• Preventer dose if prescribed and technique
• A copy for childcare or kindergarten

Spacer technique is the single highest-yield intervention. Correctly used MDI plus spacer delivers two to three times more drug to the lower airway than poor technique. Demonstrate, observe, and correct at every visit.

RSV prevention and vaccination

RSV nirsevimab (Beyfortus): NIP-funded per ATAGI 2025 for all infants eight months and under entering their first RSV season, and for high-risk infants up to twenty-four months in a second RSV season. The MELODY trial (Hammitt NEJM 2022) demonstrated a 74.5% reduction in medically attended RSV lower respiratory tract infection.

Influenza vaccine: NIP-funded from six months; offer at every autumn visit.

Managing the atopic march

MTW and atopic disease co-exist and reinforce each other. Treating allergic rhinitis aggressively — intranasal corticosteroid plus antihistamine — improves wheeze control in MTW. Early management of eczema may interrupt allergen sensitisation. Food allergy assessment and referral to a paediatric allergist is appropriate in children with strong atopic features and a positive mAPI.

D. Australian operations

MBS items: Standard GP consultations use item 23 or 36; paediatric item 44 for longer consultations; CXR item 58503 when indicated; FBC item 65070; vitamin D item 66608 if at risk; specific IgE item 71093 when aeroallergen sensitisation is suspected; ATSI Health Assessment item 715.

PBS: Salbutamol MDI (100 µg) is general schedule (also available over-the-counter). Fluticasone propionate MDI (Flixotide) for children one year and above is PBS Authority Required (Streamlined). Montelukast 4 mg granules (<6 yr) and 5 mg chewable tablets (≥6 yr) are PBS Authority Required (Streamlined) from six months — document counselling at the time of the first prescription.

Mental Health Care Plan: Relevant if montelukast neuropsychiatric adverse effects cause behavioural or sleep concerns requiring psychological support, or for significant parental mental health impact from chronic wheeze.

Parent safety-netting message: “Many children wheeze with colds in the first five years and most grow out of it by school age. The blue puffer opens the airways quickly — we give six puffs through the spacer for younger children, twelve for older, one puff at a time with four to six breaths each, and repeat every twenty minutes up to three times. Call 000 if your child can’t talk, goes limp or drowsy, turns blue around the lips, or doesn’t improve with the puffer. We’ll review in one to two weeks.”

E. Special populations

ATSI children: Aboriginal and Torres Strait Islander children have higher rates of wheeze exacerbation and hospital admission. Social determinants — household crowding, increased household smoke exposure, lower access to early preventive care — contribute to higher burden. The ATSI Health Assessment (item 715) at twelve months and two years provides structured respiratory review alongside immunisation and growth assessment.

Preterm infants: Preterm birth (particularly before 32 weeks) is associated with significantly higher rates of recurrent wheeze and lower respiratory infection in the first five years, even in the absence of bronchopulmonary dysplasia. Nirsevimab is particularly recommended for premature infants in their first RSV season.

Household smoke exposure: Tobacco and vaping exposure roughly doubles wheeze frequency and severity. Cessation support for household members is one of the highest-yield preventive interventions available. Document and offer pharmacotherapy (varenicline, nicotine replacement) and counselling to parents at every wheeze presentation.

When to escalate

Refer urgently (same-day or ED) when:

• Moderate-severe wheeze not responding to three salbutamol doses in one hour
• Suspected foreign body aspiration (sudden choking, unilateral wheeze, unequal air entry)
• SpO₂ persistently below 92% on room air
• Suspected cystic fibrosis (failure to thrive plus recurrent wheeze — confirm newborn screen, arrange sweat chloride test)
• Suspected immunodeficiency (recurrent severe infections, growth failure, family history)

Refer to paediatric respiratory clinic when:

• Two or more admissions in twelve months, or oxygen required during an episode
• mAPI positive with MTW not improving on maintenance inhaled corticosteroid
• Diagnostic uncertainty (cardiac wheeze, tracheomalacia, primary ciliary dyskinesia)
• Persistent symptoms requiring specialist guidance on preventer threshold

What this article is and is not

This is general health information drawn from current Australian guidelines — the National Asthma Council Australian Asthma Handbook, Royal Children’s Hospital Melbourne clinical practice guidelines, Therapeutic Guidelines, and ATAGI immunisation guidance — for educational purposes. It is not personal medical advice and does not create a doctor–patient relationship. Specific treatment decisions, including medication choices, preventer thresholds, and referral decisions, are made with your own GP and treating clinicians.

AU consumer resources: HealthDirect — Wheezing in children · RCH Kids Health Info — Wheeze · Asthma Australia — Children under 5 · National Asthma Council · Better Health Channel — Asthma in children.

---

Sources cited

1. National Asthma Council Australia — Australian Asthma Handbook (children 1–5, 2024 update)
2. Royal Children’s Hospital Melbourne — CPG: Asthma acute (paediatric, 2024)
3. Therapeutic Guidelines (eTG) — Respiratory: Wheezing illness in young children
4. Australian Medicines Handbook — Children’s dosing (salbutamol, ICS, prednisolone, montelukast)
5. TGA — Montelukast (Singulair) Boxed Warning 2020
6. ATAGI — Australian Immunisation Handbook: RSV nirsevimab 2025
7. Asthma Australia — Pre-school asthma action plan
8. HealthDirect — Wheezing in children
9. Better Health Channel — Asthma in children
10. GINA — Diagnosis and management of asthma in children 5 years and younger, 2024
11. Bacharier LB et al. — PRACTALL consensus: asthma in childhood. Allergy 2008;63:5-34
12. Castro-Rodríguez JA et al. — Asthma Predictive Index. AJRCCM 2000;162:1403
13. Guilbert TW et al. — PEAK trial: long-term ICS in preschool children at high risk for asthma. NEJM 2006;354:1985
14. Panickar J et al. — MIST trial: oral prednisolone for preschool viral wheeze. NEJM 2009;360:329
15. Schuh S et al. — Dexamethasone in preschool viral wheeze. NEJM 2009
16. Hammitt LL et al. — MELODY trial: nirsevimab for RSV. NEJM 2022;386:837
17. MBS Online — items 23, 36, 44, 58503, 65070, 66608, 71093, 715
18. National Asthma Council Australia — paediatric resources